Effect of Mirabegron to Reduce Lower Urinary Tract Symptoms in Prostatitis

Aim: To investigate effectiveness and safety of mirabegron in a patient’s symptoms associated with prostatitis routine practice. Study Design: Prospective, pilot study Place Duration Study: Department Urology, Liaquat University Hospital Jamshoro between 1st October 2020 30th November 2021 Methodology: Fifteen male subjects two groups (control treatment group Mirabegron), 18 to 50 years old, acute chronic according the operational definition were recruited. The overactive bladder started at daily doses 25mg, 50mg, 100 mg respectively. Results: mean ages 47.7±2.1 33.8±7.0 respectively control groups. significant efficacy treating OAB such as frequent urination, urge incontinence, urgency. For mg, volume urine passed per micturition was observed early first assessment after 4-week’s duration remained stable throughout for up 12 months. In terms dry rates, our analyses revealed considerable improvement 50mg mg. Patients considered their be worthwhile, an analysis satisfaction criteria. Mirabegron safe clinical trials that lasted Conclusion: When contrasted existing antimuscarinics restricted due adverse effects insufficient effectiveness, found improved compliance balance Pakistani patients prostatitis. Key words: Prostatitis, Mirabegron, Effectiveness